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Importance of dietary calcium and vitamin D in the 
treatment of hypercalcaemia in Williams-Beuren 
syndrome
Abstract
Background: Williams-Beuren syndrome (WBS) is a rare 
genetic disorder caused by the deletion of 26–28 genes on 
chromosome 7. Fifteen percent of WBS patients present 
with hypercalcaemia during infancy, which is generally 
mild and resolves spontaneously before the age of 4 years. 
The mechanisms underlying the transient hypercalcae-
mia in WBS are poorly understood.
Case: We report a case of severe symptomatic hypercalcae-
mia in a patient with WBS, in which treatment with mild 
calcium restriction, hyperhydration and repeated bisphos-
phonate administration only resulted in short-lasting 
effects. Long-term lowering of serum calcium was only 
achieved after reducing calcium and vitamin D intake to 
the bare minimum.
Conclusions: This case illustrates the potential severity of 
hypercalcaemia in WBS, and demonstrates that both the 
cause as well as the solution of this problem may be found 
in the intestinal absorption of calcium. We hypothesise 
that the phenotypical resemblance between WBS and tran-
sient idiopathic infantile hypercalcaemia can be explained 
by similarities in the underlying genetic defect. Patients 
suffering from transient infantile hypercalcaemia were 
recently described to have mutations in CYP24A1, the key 
enzyme in 1,25-dihydroxyvitamin D3 degradation. In the 
light of this new development we discuss the role of one of 
the deleted genes in WBS, Williams syndrome transcription 
factor (WSTF  ), in the etiology of hypercalcaemia in WBS.
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Introduction
Williams-Beuren syndrome (WBS, OMIM 194050) is a 
rare genetic disorder caused by a hemizygous deletion 
at 7q11.23 comprising approximately 26–28 genes (1). 
Patients with WBS are generally characterised by distinc-
tive facial dysmorphisms, mental retardation and cardio-
vascular abnormalities. In addition, approximately 15% of 
WBS patients present with hypercalcaemia during infancy, 
which is generally mild in nature. It resolves spontane-
ously before the age of 4 years, but sometimes reoccurs 
briefly during puberty (1). The mechanisms explaining 
the transient hypercalcaemia are poorly understood. We 
report a case of severe symptomatic hypercalcaemia in a 
patient with WBS only resolving with a profound reduc-
tion in calcium and vitamin D intake, and present a poten-
tial mechanism for this metabolic abnormality.
Case report
An 18-month-old female patient was admitted to a local 
hospital to start tube feeding for treatment of failure to 
thrive due to feeding difficulties and persistent vomiting 
despite proton-pump inhibition. Three months earlier 
she was diagnosed with WBS with normal serum calcium 
levels (2.40 mmol/L), and was born with a low birth 
weight, a cardiac murmur without a structural anomaly, 
and a developmental delay.
During her admission, her condition deteriorated, 
and she developed hypercalcaemia (Table 1) and hyper-
tension (up to 150/130 mm Hg) for which she was trans-
ferred to the paediatric intensive care unit at the Radboud 
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Radboud University Medical Center. Her blood pressure 
was controlled with an intravenous calcium-antagonist, 
which was successfully switched to oral anti-hypertensive 
agents (amlodipine and labetalol). Extensive evaluation, 
excluding renal angiography, did not show an explana-
tion for the hypertension, other than the hypercalcaemia 
and the underlying WBS.
The hypercalcaemia was treated with hyperhydration, 
furosemide and a reduced calcium intake. Laboratory tests 
ruled out other causes than the WBS for the hypercalcae-
mia (Table 1). To prevent nephrocalcinosis due to the sub-
sequent hypercalciuria (urine calcium-creatinine ratio up 
to 3.0 mmol/mmol) potassium citrate was administered.
As this treatment only led to a small reduction in 
serum calcium (Figure 1), a bisphosphonate was adminis-
tered in a low dose to prevent hypocalcaemia. This resulted 
in only a short and mild reduction in the serum calcium; 
so repeated and increased doses of pamidronate were 
administered, all with only short-lasting effects (Figure 1). 
With every return of hypercalcaemia, the patient also 
showed an increase in blood pressure and vomiting. There-
fore, calcium and vitamin D intake (drip-feed containing 
588 mg/day and 150 IE/day, respectively) was reduced to 
the bare minimum (68 mg/day and 0 IE/day, respectively) 
while maintaining adequate nutritional intake. With this 
treatment, serum calcium was maintained at high-normal 
but stable levels that were clinically well accepted. Phos-
phate supplementation was initiated to treat her accom-
panying hypophosphataemia.
During follow-up, we found to our surprise a low renal 
calcium excretion and high parathyroid hormone (PTH) 
level during the calcium restriction. We interpreted this to 
be indicative of a more calcium-deficient state, despite the 
high-normal serum calcium, for which the calcium intake 
was gradually increased. No nephrocalcinosis is present 
at the latest ultrasound, and no hypercalciuria occurred 
during the gradual increase in calcium intake.
Discussion
In the past, various studies have been performed to try 
and elucidate the mechanism underlying hypercalcaemia 
in WBS. We hypothesise that increased intestinal absorp-
tion of calcium is the main factor in the pathogenesis of 
hypercalcaemia in these patients, as has been described 
in the past (2), potentially as a result of reduced break-
down of vitamin D. Most studies aimed to find changes in 
vitamin D metabolism, with various degrees of success. 
Some groups find abnormalities in all patients suffer-
ing from WBS, whereas others only describe changes in 
vitamin D metabolism in WBS patients with hypercalcae-
mia, and some groups find no changes at all (3).
Bisphosphonate therapy (pamidronate) is recom-
mended as an additional therapy when conventional 
measures (intravenous fluids, furosemide and dietary 
calcium restriction) fail to normalise serum calcium. 
However, the course of the hypercalcaemia in our patient 
seems to suggest no sustained effect of bisphosphonate 
treatment and suggests an intestinal cause of hypercal-
caemia that can only be treated by (extensive) calcium 
and vitamin D restriction. It is to be noted that our patient 
did not show extensive hypercalciuria at presentation 
(Table  1), which would be expected in hypercalcaemia. 
However, renal function was reduced at that time with an 
Table 1 Laboratory parameters at diagnosis and during follow-up.
Parameter   Normal range  Hospital admission 
for hypercalcaemia
  3 months after 
admission
  6 months after 
admission
  Latest follow-up
Age     1 year, 6 months  1 year, 9 months  2 years, 1 month  4 years, 6 months
Total calcium, mmol/L   2.20–2.70  3.51  2.61  2.76  2.73
Calcium ion, mmol/L   1.10–1.30  ND  1.33  1.37  1.26
Albumin, g/L   35–50  45.0  44  52  ND
Phosphate, mmol/L   1.5–2.2  1.5  1.72  1.54  1.26
eGFR, mL/min/1.73 m2   90–120  41  129  114  ND
25-(OH)-vitamin D, nmol/L   18–113  56.7  46  38  ND
1,25-(OH)-vitamin D, pmol/L   47–130  18.7  ND  250  ND
PTH, pmol/L   1.3–6.8  0.4  9.9  6.2  2.7
Urine calcium-creatinine ratio, 
mmol/mmol
   < 1.5  1.15   < 0.3   < 0.3  0.55
ND, not determined; eGFR, estimated glomerular filtration rate based on the Schwartz equation; PTH, parathyroid hormone.
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estimated glomerular filtration rate of 41 mL/min/1.73 m2 
and hypercalciuria did present after optimising renal func-
tion (urine calcium-creatinine ratio up to 3.0 mmol/mmol). 
The reduced renal function may explain the temporary 
absence of hypercalciuria, and may have contributed to 
the observed hypercalcaemia. The persisting hypercalciu-
ria as well as hypercalcaemia that were observed when 
renal function was restored indicate that the hypercalcae-
mia in our patient is not solely explained by inappropriate 
renal calcium handling due to renal failure. Some of the 
features of our patient are not easily explained and may 
indicate an additional factor involved in the aetiology of 
hypercalcaemia in this particular patient. The high PTH 
levels observed after 3–6 months, when serum calcium 
levels are in the high-normal range could also indicate an 
altered set point of serum calcium, which is commonly 
associated with inactivating mutations in the calcium-
sensing receptor (CaSR).
Hypertension is, in addition to the hypercalcaemia, a 
well-known feature in up to 50% of WBS patients and may 
be explained by elastin deficiency, a hallmark feature of 
WBS (1). Alternatively, renal artery stenosis is described in 
some patients with WBS, which we did not fully exclude 
in our patient yet. As blood pressure was well controlled 
with the current medical therapy, renal ultrasound 
showed identical-sized and normal-structured kidneys, 
and renography showed a normal split renal function; no 
renal angiography was performed.
Our case of severe and sustained hypercalcaemia 
highlights that the underlying mechanism in WBS can be 
found, at least in part, in the uptake of calcium, as the 
long-term lowering of serum calcium was only obtained 
by a subtotal reduction in the calcium and vitamin D 
intake. Hypercalcaemia in WBS patients and patients 
suffering from IIH without WBS both have been shown 
to result from intestinal hyperabsorption of calcium, 
the contribution of potential changes in renal calcium 
handling to the observed hypercalcaemia remains to be 
determined (2).
Similar to our WBS patient, IIH patients were shown 
to benefit from dietary calcium and vitamin D restriction 
(4). Patients should, however, be carefully monitored as 
long-term restriction of dietary calcium and vitamin D 
may induce rickets in these young patients (4, 5).
Based on these phenotypical similarities between 
patients with WBS and IIH, we previously suggested there 
might be a common underlying genetic defect (6). We 
hypothesised that claudin 3 and claudin 4, both involved 
in paracellular calcium absorption and located within the 
hemizygously deleted WBS region, might be responsible 
for the hypercalcaemia state of these patients. Unfor-
tunately, we were not able to confirm this hypothesis in 
patients suffering from isolated infantile hypercalcaemia 
(6). Letavernier et  al. suggested that hypercalcaemia in 
WBS patients is the result of TRPC3 overexpression due 
to haploinsufficiency of the transcriptions factor TFII-I, 
which is located in the genomic region that is deleted in 
WBS patients (7). Evidence that TRPC3 is involved in tran-
sepithelial calcium transport in the intestine, however, 
is lacking. Despite the earlier negative findings, our 
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Figure 1 Time course of total calcium and ionised calcium levels in serum during treatment and follow-up.
Grey areas indicate the normal range total serum calcium (2.20–2.70 mmol/L) and ionised calcium (1.10–1.30 mmol/L). The arrows indicate 
interventions. 1–4: Intravenous administration of pamidronate, 0.25, 0.50, 1.0, and 1.0 mg pamidronate/kg body weight, respectively. 
5: Diet changed from drip-feed containing 588 mg Ca/day and 150 IE 1,25-dihydroxyvitamin D3/day to a drip-feed with 68 mg Ca/day and 
0 IE 1,25-dihydroxyvitamin D3/day.
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hypothesis remains valid. The similarities with regard to 
the transient hypercalcaemic phenotype of IIH and WBS 
patients suggest a common underlying genetic defect. 
Interestingly, the genetic defect causing IIH has recently 
been elucidated, shedding more light on the molecular 
mechanism underlying hypercalcaemia in these patients. 
Two independent studies have found that homozygous 
or compound heterozygous mutations and deletions in 
the CYP24A1 gene are responsible for the phenotype of 
patients suffering from IIH. CYP24A1 encodes 25-dihy-
droxyvitamin D 24-hydroxylase, which is the key enzyme 
in 1,25-dihydroxyvitamin D3 degradation (8, 9). Patients 
display hypercalcaemia, hypercalciuria, and suppressed 
PTH levels, whereas levels of 25-hydroxyvitamin D3 and 
1,25-dihydroxyvitamin D3 were within normal range. A 
third study describes patients with a heterozygous muta-
tion in CYP24A1 that has a less severe clinical pheno-
type compared to the compound heterozygous patients, 
indicative of a haploinsufficiency or a dominant nega-
tive effect (10). This study also shows that patients with 
CYP24A1 mutations have reduced levels of circulating 
24,25-dihydroxyvitamin D3 in line with a non-functional 
Cyp24a1 enzyme. Together, these studies indicate that in 
IIH patients, intestinal hyperabsorption of calcium is the 
result of altered vitamin D catabolism.
Interestingly, a gene named WSTF is located within 
the WBS deletion region. WSTF is a subunit of the ATP-
dependent chromatin remodeling complex WINAC, whose 
activity facilitates ligand-dependent activation of CYP24A1 
and repression of 25-hydroxyvitamin D3-1-alpha hydroxy-
lase (CYP27B1) by the vitamin D receptor (11).
It has been previously hypothesised that hypercalcae-
mia in WBS is the result of loss of WINAC function, leading 
to reduced transcription of CYP24A1 and increased tran-
scription of CYP27B1, theoretically resulting in increased 
1,25-dihydroxyvitamin D3 (12). Lack of a clear increase in 
1,25-dihydroxyvitamin D3 levels in WBS patients seems 
to contradict this hypothesis. However, the phenotype of 
patients with CYP24A1 mutations clearly demonstrates 
that a lack of 25-dihydroxyvitamin D 24-hydroxylase may 
indeed lead to a hypercalcaemic phenotype without a 
clear increase in circulating 1,25-dihydroxyvitamin D3 
levels; only the patients receiving large doses of vitamin 
D prophylaxis display elevated levels of circulating 
1,25-dihydroxyvitamin D3 (9). As our patient was admitted 
for failure to thrive, it is safe to assume that her vitamin 
D intake was low. Similar observations have been made 
in Cyp24a1 knockout mice, which have normal 1,25-dihy-
droxyvitamin D3 levels at baseline, but show an impaired 
clearance of administered 1,25-dihydroxyvitamin D3 (13). 
The exact explanation for this finding remains to be 
determined, but it strengthens the hypothesis that the 
hemizygous deletion of WSTF could be responsible for the 
transient hypercalcaemia in WBS, despite a lack of clear 
alterations in 1,25-dihydroxyvitamin D3. These data are 
in line with our hypothesis that deletion of WSTF in WBS 
patients leads to a reduced CYP24A1 activity, therefore, a 
reduced catabolism of 1,25-dihydroxyvitamin D3, which 
results in increased intestinal calcium absorption with 
subsequent hypercalcaemia.
In conclusion, our patient illustrates the potential 
severity of hypercalcaemia in WBS, and demonstrates that 
both the cause and the solution of this problem may be 
found in the intestinal absorption of calcium. Key to treat-
ment of severe hypercalcaemia in WBS is subtotal restric-
tion of calcium and vitamin D intake. Follow-up should 
include careful monitoring of serum and urinary calcium 
levels, to navigate between hypercalcaemia and calcium 
depletion.
Support and Financial Disclosure
None of the authors received support for the current man-
uscript. None of the authors has a potential conflict of 
interest to declare.
Received June 4, 2013; accepted January 14, 2014; previously published 
online February 27, 2014
References
1. Pober BR. Williams-Beuren syndrome. N Engl J Med 
2010;362:239–52.
2. Barr DG, Forfar JO. Oral calcium-loading test in infancy, with 
particular reference to idiopathic hypercalcaemia. Br Med J 
1969;1:477–80.
3. Kruse K, Pankau R, Gosch A, Wohlfahrt K. Calcium metabolism in 
Williams-Beuren syndrome. J Pediatr 1992;121:902–7.
4. Martin ND, Snodgrass GJ, Cohen RD. Idiopathic infantile 
hypercalcaemia—a continuing enigma. Arch Dis Child 
1984;59:605–13.
5. Gut J, Kutilek S. Idiopathic infantile hypercalcaemia in 
5-month-old girl. Prague Med Rep 2011;112:124–31.
6. Lameris AL, Huybers S, Burke JR, Monnens LA, Bindels RJ, 
Hoenderop JG. Involvement of claudin 3 and claudin 4 in 
Brought to you by | provisional account
Unauthenticated
Download Date | 12/23/19 3:13 PM
Lameris et al.: Treatment of hypercalcaemia in Williams-Beuren syndrome      761
 idiopathic infantile hypercalcaemia: a novel hypothesis?  
Nephrol Dial Transplant 2010;25:3504–9.
7. Letavernier E, Rodenas A, Guerrot D, Haymann JP. Williams-
Beuren syndrome hypercalcemia: is TRPC3 a novel mediator in 
calcium homeostasis? Pediatrics 2012;129:e1626–30.
8. Dauber A, Nguyen TT, Sochett E, Cole DE, Horst R, et al. Genetic 
defect in CYP24A1, the vitamin D 24-hydroxylase gene, in a 
patient with severe infantile hypercalcemia. J Clin Endocrinol 
Metab 2012;97:E268–74.
9. Schlingmann KP, Kaufmann M, Weber S, Irwin A, Goos C, et al. 
Mutations in CYP24A1 and idiopathic infantile hypercalcemia.  
N Engl J Med 2011;365:410–21.
10. Tebben PJ, Milliner DS, Horst RL, Harris PC, Singh RJ, et al. 
Hypercalcemia, hypercalciuria, and elevated calcitriol concen-
trations with autosomal dominant transmission due to CYP24A1 
mutations: effects of ketoconazole therapy. J Clin Endocrinol 
Metab 2012;97:E423–7.
11. Barnett C, Krebs JE. WSTF does it all: a multifunctional protein 
in transcription, repair, and replication. Biochem Cell Biol 
2011;89:12–23.
12. Yoshimura K, Kitagawa H, Fujiki R, Tanabe M, Takezawa S,  
et al. Distinct function of 2 chromatin remodeling complexes 
that share a common subunit, Williams syndrome 
transcription factor (WSTF). Proc Natl Acad Sci USA 
2009;106:9280–5.
13. St-Arnaud R, Arabian A, Travers R, Barletta F, Raval-Pandya M, 
et al. Deficient mineralization of intramembranous bone 
in vitamin D-24-hydroxylase-ablated mice is due to 
elevated 1,25-dihydroxyvitamin D and not to the absence of 
24,25-dihydroxyvitamin D. Endocrinology 2000;141:2658–66.
Brought to you by | provisional account
Unauthenticated
Download Date | 12/23/19 3:13 PM
